155 related articles for article (PubMed ID: 38029742)
1. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
[TBL] [Abstract][Full Text] [Related]
2. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
[TBL] [Abstract][Full Text] [Related]
3. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
[TBL] [Abstract][Full Text] [Related]
4. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
[TBL] [Abstract][Full Text] [Related]
5. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
[TBL] [Abstract][Full Text] [Related]
6. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
Li J; Gong L; Li J; Gong Z; Wang X; Yan H; Zhang Y; Mao H; Chen K
Vaccine; 2024 Jul; 42(18):3751-3755. PubMed ID: 38714449
[TBL] [Abstract][Full Text] [Related]
7. Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Suryawanshi RK; Taha TY; McCavitt-Malvido M; Silva I; Khalid MM; Syed AM; Chen IP; Saldhi P; Sreekumar B; Montano M; Foresythe K; Tabata T; Kumar GR; Sotomayor-Gonzalez A; Servellita V; Gliwa A; Nguyen J; Kojima N; Arellanor T; Bussanich A; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Wang Y; Ghazarian S; Davis G; Rodriguez D; Doudna J; Spraggon L; Chiu CY; Ott M
Emerg Microbes Infect; 2023 Dec; 12(2):2270071. PubMed ID: 37869789
[TBL] [Abstract][Full Text] [Related]
8. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
10. Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.
Chang S; Shin KS; Park B; Park S; Shin J; Park H; Jung IK; Kim JH; Bae SE; Kim JO; Baek SH; Kim G; Hong JJ; Seo H; Volz E; Kang CY
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2313681121. PubMed ID: 38408238
[TBL] [Abstract][Full Text] [Related]
11. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
[TBL] [Abstract][Full Text] [Related]
12. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
[TBL] [Abstract][Full Text] [Related]
13. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
14. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy.
Trombetta CM; Marchi S; Leonardi M; Coppola C; Benincasa L; Marotta MG; Buonvino N; Maes P; Stufano A; Pontrelli D; Vasinioti VI; Manenti A; Camero M; Montomoli E; Decaro N; Lovreglio P
Acta Trop; 2023 Dec; 248():107042. PubMed ID: 37863379
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
J Virol; 2024 Jul; ():e0067824. PubMed ID: 38953380
[TBL] [Abstract][Full Text] [Related]
17. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
[TBL] [Abstract][Full Text] [Related]
18. Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
Liang Z; Tong J; Sun Z; Liu S; Wu J; Wu X; Li T; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
J Med Virol; 2024 Jan; 96(1):e29314. PubMed ID: 38163276
[TBL] [Abstract][Full Text] [Related]
19. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
[TBL] [Abstract][Full Text] [Related]
20. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
